Skip to content
TrialScanner

NCT03290950

A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma

Phase 2Active, not recruitingJNJCollaborator

Registry record

Lead sponsor
Memorial Sloan Kettering Cancer Center
Conditions
Multiple Myeloma
Primary completion
May 21, 2025Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03290950 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

1 change recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03290950: A Study of Daratumumab in... | TrialScanner